1 Study Coverage 1.1 Neurofibromatoses Type II Therapecutics Product Introduction 1.2 Market by Type 1.2.1 Global Neurofibromatoses Type II Therapecutics Market Size Growth Rate by Type 1.4.2 AR-42 1.4.3 FRAX-597 1.2.4 Icotinib Hydrochloride 1.2.5 LB-201 1.2.6 LB-205 1.2.7 Others 1.3 Market by Application 1.3.1 Global Neurofibromatoses Type II Therapecutics Market Size Growth Rate by Application 1.3.2 Clinic 1.3.3 Hospital 1.3.4 Home Care 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global Neurofibromatoses Type II Therapecutics Sales Estimates and Forecasts 2016-2027 2.2 Global Neurofibromatoses Type II Therapecutics Revenue Estimates and Forecasts 2016-2027 2.3 Global Neurofibromatoses Type II Therapecutics Revenue by Region: 2016 VS 2021 VS 2027 2.4 Global Top Neurofibromatoses Type II Therapecutics Regions by Sales 2.4.1 Global Top Neurofibromatoses Type II Therapecutics Regions by Sales (2016-2021) 2.4.2 Global Top Neurofibromatoses Type II Therapecutics Regions by Sales (2022-2027) 2.5 Global Top Neurofibromatoses Type II Therapecutics Regions by Revenue 2.5.1 Global Top Neurofibromatoses Type II Therapecutics Regions by Revenue (2016-2021) 2.5.2 Global Top Neurofibromatoses Type II Therapecutics Regions by Revenue (2022-2027) 2.6 North America 2.7 Europe 2.8 Asia-Pacific 2.9 Latin America 2.10 Middle East & Africa 3 Competition by Manufacturers 3.1 Global Neurofibromatoses Type II Therapecutics Sales by Manufacturers 3.1.1 Global Top Neurofibromatoses Type II Therapecutics Manufacturers by Sales (2016-2021) 3.1.2 Global Top Neurofibromatoses Type II Therapecutics Manufacturers Market Share by Sales (2016-2021) 3.1.3 Global Top 10 and Top 5 Companies by Neurofibromatoses Type II Therapecutics Sales in 2020 3.2 Global Neurofibromatoses Type II Therapecutics Revenue by Manufacturers 3.2.1 Global Top Neurofibromatoses Type II Therapecutics Manufacturers by Revenue (2016-2021) 3.2.2 Global Top Neurofibromatoses Type II Therapecutics Manufacturers Market Share by Revenue (2016-2021) 3.2.3 Global Top 10 and Top 5 Companies by Neurofibromatoses Type II Therapecutics Revenue in 2020 3.3 Global Neurofibromatoses Type II Therapecutics Sales Price by Manufacturers 3.4 Analysis of Competitive Landscape 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Neurofibromatoses Type II Therapecutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.4.3 Global Neurofibromatoses Type II Therapecutics Manufacturers Geographical Distribution 3.5 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type 4.1 Global Neurofibromatoses Type II Therapecutics Sales by Type 4.1.1 Global Neurofibromatoses Type II Therapecutics Historical Sales by Type (2016-2021) 4.1.2 Global Neurofibromatoses Type II Therapecutics Forecasted Sales by Type (2022-2027) 4.1.3 Global Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2027) 4.2 Global Neurofibromatoses Type II Therapecutics Revenue by Type 4.2.1 Global Neurofibromatoses Type II Therapecutics Historical Revenue by Type (2016-2021) 4.2.2 Global Neurofibromatoses Type II Therapecutics Forecasted Revenue by Type (2022-2027) 4.2.3 Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2016-2027) 4.3 Global Neurofibromatoses Type II Therapecutics Price by Type 4.3.1 Global Neurofibromatoses Type II Therapecutics Price by Type (2016-2021) 4.3.2 Global Neurofibromatoses Type II Therapecutics Price Forecast by Type (2022-2027) 5 Market Size by Application 5.1 Global Neurofibromatoses Type II Therapecutics Sales by Application 5.1.1 Global Neurofibromatoses Type II Therapecutics Historical Sales by Application (2016-2021) 5.1.2 Global Neurofibromatoses Type II Therapecutics Forecasted Sales by Application (2022-2027) 5.1.3 Global Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2027) 5.2 Global Neurofibromatoses Type II Therapecutics Revenue by Application 5.2.1 Global Neurofibromatoses Type II Therapecutics Historical Revenue by Application (2016-2021) 5.2.2 Global Neurofibromatoses Type II Therapecutics Forecasted Revenue by Application (2022-2027) 5.2.3 Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2016-2027) 5.3 Global Neurofibromatoses Type II Therapecutics Price by Application 5.3.1 Global Neurofibromatoses Type II Therapecutics Price by Application (2016-2021) 5.3.2 Global Neurofibromatoses Type II Therapecutics Price Forecast by Application (2022-2027) 6 North America 6.1 North America Neurofibromatoses Type II Therapecutics Market Size by Type 6.1.1 North America Neurofibromatoses Type II Therapecutics Sales by Type (2016-2027) 6.1.2 North America Neurofibromatoses Type II Therapecutics Revenue by Type (2016-2027) 6.2 North America Neurofibromatoses Type II Therapecutics Market Size by Application 6.2.1 North America Neurofibromatoses Type II Therapecutics Sales by Application (2016-2027) 6.2.2 North America Neurofibromatoses Type II Therapecutics Revenue by Application (2016-2027) 6.3 North America Neurofibromatoses Type II Therapecutics Market Size by Country 6.3.1 North America Neurofibromatoses Type II Therapecutics Sales by Country (2016-2027) 6.3.2 North America Neurofibromatoses Type II Therapecutics Revenue by Country (2016-2027) 6.3.3 U.S. 6.3.4 Canada 7 Europe 7.1 Europe Neurofibromatoses Type II Therapecutics Market Size by Type 7.1.1 Europe Neurofibromatoses Type II Therapecutics Sales by Type (2017-2027) 7.1.2 Europe Neurofibromatoses Type II Therapecutics Revenue by Type (2017-2027) 7.2 Europe Neurofibromatoses Type II Therapecutics Market Size by Application 7.2.1 Europe Neurofibromatoses Type II Therapecutics Sales by Application (2017-2027) 7.2.2 Europe Neurofibromatoses Type II Therapecutics Revenue by Application (2017-2027) 7.3 Europe Neurofibromatoses Type II Therapecutics Market Size by Country 7.3.1 Europe Neurofibromatoses Type II Therapecutics Sales by Country (2017-2027) 7.3.2 Europe Neurofibromatoses Type II Therapecutics Revenue by Country (2017-2027) 7.3.3 Germany 7.3.4 France 7.3.5 U.K. 7.3.6 Italy 7.3.7 Russia 8 Asia Pacific 8.1 Asia Pacific Neurofibromatoses Type II Therapecutics Market Size by Type 8.1.1 Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Type (2018-2027) 8.1.2 Asia Pacific Neurofibromatoses Type II Therapecutics Revenue by Type (2018-2027) 8.2 Asia Pacific Neurofibromatoses Type II Therapecutics Market Size by Application 8.2.1 Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Application (2018-2027) 8.2.2 Asia Pacific Neurofibromatoses Type II Therapecutics Revenue by Application (2018-2027) 8.3 Asia Pacific Neurofibromatoses Type II Therapecutics Market Size by Region 8.3.1 Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Region (2018-2027) 8.3.2 Asia Pacific Neurofibromatoses Type II Therapecutics Revenue by Region (2018-2027) 8.3.3 China 8.3.4 Japan 8.3.5 South Korea 8.3.6 India 8.3.7 Australia 8.3.8 Taiwan 8.3.9 Indonesia 8.3.10 Thailand 8.3.11 Malaysia 8.3.12 Philippines 9 Latin America 9.1 Latin America Neurofibromatoses Type II Therapecutics Market Size by Type 9.1.1 Latin America Neurofibromatoses Type II Therapecutics Sales by Type (2019-2027) 9.1.2 Latin America Neurofibromatoses Type II Therapecutics Revenue by Type (2019-2027) 9.2 Latin America Neurofibromatoses Type II Therapecutics Market Size by Application 9.2.1 Latin America Neurofibromatoses Type II Therapecutics Sales by Application (2019-2027) 9.2.2 Latin America Neurofibromatoses Type II Therapecutics Revenue by Application (2019-2027) 9.3 Latin America Neurofibromatoses Type II Therapecutics Market Size by Country 9.3.1 Latin America Neurofibromatoses Type II Therapecutics Sales by Country (2019-2027) 9.3.2 Latin America Neurofibromatoses Type II Therapecutics Revenue by Country (2019-2027) 9.3.3 Mexico 9.3.4 Brazil 9.3.5 Argentina 6 Middle East and Africa 6.1 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size by Type 6.1.1 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Type (2016-2027) 6.1.2 Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue by Type (2016-2027) 6.2 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size by Application 6.2.1 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Application (2016-2027) 6.2.2 Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue by Application (2016-2027) 6.3 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size by Country 6.3.1 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country (2016-2027) 6.3.2 Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue by Country (2016-2027) 6.3.3 Turkey 6.3.4 Saudi Arabia 6.3.5 U.A.E 11 Company Profiles 11.1 Arno Therapeutics Inc 11.1.1 Arno Therapeutics Inc Corporation Information 11.1.2 Arno Therapeutics Inc Overview 11.1.3 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Sales, Price, Revenue and Gross Margin (2016-2021) 11.1.4 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Product Description 11.1.5 Arno Therapeutics Inc Related Developments 11.2 AstraZeneca Plc 11.2.1 AstraZeneca Plc Corporation Information 11.2.2 AstraZeneca Plc Overview 11.2.3 AstraZeneca Plc Neurofibromatoses Type II Therapecutics Sales, Price, Revenue and Gross Margin (2016-2021) 11.2.4 AstraZeneca Plc Neurofibromatoses Type II Therapecutics Product Description 11.2.5 AstraZeneca Plc Related Developments 11.3 Beta Pharma Inc 11.3.1 Beta Pharma Inc Corporation Information 11.3.2 Beta Pharma Inc Overview 11.3.3 Beta Pharma Inc Neurofibromatoses Type II Therapecutics Sales, Price, Revenue and Gross Margin (2016-2021) 11.3.4 Beta Pharma Inc Neurofibromatoses Type II Therapecutics Product Description 11.3.5 Beta Pharma Inc Related Developments 11.4 Lixte Biotechnology Holdings Inc 11.4.1 Lixte Biotechnology Holdings Inc Corporation Information 11.4.2 Lixte Biotechnology Holdings Inc Overview 11.4.3 Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Sales, Price, Revenue and Gross Margin (2016-2021) 11.4.4 Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Product Description 11.4.5 Lixte Biotechnology Holdings Inc Related Developments 11.5 Plex Pharmaceuticals Inc 11.5.1 Plex Pharmaceuticals Inc Corporation Information 11.5.2 Plex Pharmaceuticals Inc Overview 11.5.3 Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales, Price, Revenue and Gross Margin (2016-2021) 11.5.4 Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Description 11.5.5 Plex Pharmaceuticals Inc Related Developments 11.6 Recursion Pharmaceuticals Inc 11.6.1 Recursion Pharmaceuticals Inc Corporation Information 11.6.2 Recursion Pharmaceuticals Inc Overview 11.6.3 Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales, Price, Revenue and Gross Margin (2016-2021) 11.6.4 Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Description 11.6.5 Recursion Pharmaceuticals Inc Related Developments 11.1 Arno Therapeutics Inc 11.1.1 Arno Therapeutics Inc Corporation Information 11.1.2 Arno Therapeutics Inc Overview 11.1.3 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Sales, Price, Revenue and Gross Margin (2016-2021) 11.1.4 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Product Description 11.1.5 Arno Therapeutics Inc Related Developments 12 Value Chain and Sales Channels Analysis 12.1 Neurofibromatoses Type II Therapecutics Value Chain Analysis 12.2 Neurofibromatoses Type II Therapecutics Key Raw Materials 12.2.1 Key Raw Materials 12.2.2 Raw Materials Key Suppliers 12.3 Neurofibromatoses Type II Therapecutics Production Mode & Process 12.4 Neurofibromatoses Type II Therapecutics Sales and Marketing 12.4.1 Neurofibromatoses Type II Therapecutics Sales Channels 12.4.2 Neurofibromatoses Type II Therapecutics Distributors 12.5 Neurofibromatoses Type II Therapecutics Customers 13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis 13.1 Neurofibromatoses Type II Therapecutics Industry Trends 13.2 Neurofibromatoses Type II Therapecutics Market Drivers 13.3 Neurofibromatoses Type II Therapecutics Market Challenges 13.4 Neurofibromatoses Type II Therapecutics Market Restraints 14 Key Findings in The Global Neurofibromatoses Type II Therapecutics Study 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Author Details 15.3 Disclaimer

List of Tables Table 1. Global Neurofibromatoses Type II Therapecutics Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million) Table 2. Major Manufacturers of AR-42 Table 3. Major Manufacturers of FRAX-597 Table 4. Major Manufacturers of Icotinib Hydrochloride Table 5. Major Manufacturers of LB-201 Table 6. Major Manufacturers of LB-205 Table 7. Major Manufacturers of Others Table 8. Global Neurofibromatoses Type II Therapecutics Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million) Table 9. Global Neurofibromatoses Type II Therapecutics Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million) Table 10. Global Neurofibromatoses Type II Therapecutics Sales by Region (2016-2021) & (K Pcs) Table 11. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Region (2016-2021) Table 12. Global Neurofibromatoses Type II Therapecutics Sales by Region (2016-2021) & (K Pcs) Table 13. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Region (2022-2027) Table 14. Global Neurofibromatoses Type II Therapecutics Revenue by Region (2016-2021) & (US$ Million) Table 15. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Region (2016-2021) Table 16. Global Neurofibromatoses Type II Therapecutics Revenue by Region (2022-2027) & (US$ Million) Table 17. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Region (2022-2027) Table 18. Global Neurofibromatoses Type II Therapecutics Sales by Manufacturers (2016-2021) & (K Pcs) Table 19. Global Neurofibromatoses Type II Therapecutics Sales Share by Manufacturers (2016-2021) Table 20. Global Neurofibromatoses Type II Therapecutics Revenue by Manufacturers (2016-2021) & (US$ Million) Table 21. Global Neurofibromatoses Type II Therapecutics Revenue Share by Manufacturers (2016-2021) Table 22. Neurofibromatoses Type II Therapecutics Price by Manufacturers 2016-2021 (USD/Pcs) Table 23. Global Neurofibromatoses Type II Therapecutics Manufacturers Market Concentration Ratio (CR5 and HHI) Table 24. Global Neurofibromatoses Type II Therapecutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurofibromatoses Type II Therapecutics as of 2020) Table 25. Neurofibromatoses Type II Therapecutics Manufacturing Base Distribution and Headquarters Table 26. Manufacturers Neurofibromatoses Type II Therapecutics Product Offered Table 27. Date of Manufacturers Enter into Neurofibromatoses Type II Therapecutics Market Table 28. Mergers & Acquisitions, Expansion Plans Table 29. Global Neurofibromatoses Type II Therapecutics Sales by Type (2016-2021) & (K Pcs) Table 30. Global Neurofibromatoses Type II Therapecutics Sales by Type (2022-2027) & (K Pcs) Table 31. Global Neurofibromatoses Type II Therapecutics Sales Share by Type (2016-2021) Table 32. Global Neurofibromatoses Type II Therapecutics Sales Share by Type (2022-2027) Table 33. Global Neurofibromatoses Type II Therapecutics Revenue by Type (2016-2021) & (US$ Million) Table 34. Global Neurofibromatoses Type II Therapecutics Revenue by Type (2022-2027) & (US$ Million) Table 35. Global Neurofibromatoses Type II Therapecutics Revenue Share by Type (2016-2021) Table 36. Global Neurofibromatoses Type II Therapecutics Revenue Share by Type (2022-2027) Table 37. Neurofibromatoses Type II Therapecutics Price by Type (2016-2021) & (USD/Pcs) Table 38. Global Neurofibromatoses Type II Therapecutics Price Forecast by Type (2022-2027) & (USD/Pcs) Table 39. Global Neurofibromatoses Type II Therapecutics Sales by Application (2016-2021) & (K Pcs) Table 40. Global Neurofibromatoses Type II Therapecutics Sales by Application (2022-2027) & (K Pcs) Table 41. Global Neurofibromatoses Type II Therapecutics Sales Share by Application (2016-2021) Table 42. Global Neurofibromatoses Type II Therapecutics Sales Share by Application (2022-2027) Table 43. Global Neurofibromatoses Type II Therapecutics Revenue by Application (2016-2021) & (US$ Million) Table 44. Global Neurofibromatoses Type II Therapecutics Revenue by Application (2022-2027) & (US$ Million) Table 45. Global Neurofibromatoses Type II Therapecutics Revenue Share by Application (2016-2021) Table 46. Global Neurofibromatoses Type II Therapecutics Revenue Share by Application (2022-2027) Table 47. Neurofibromatoses Type II Therapecutics Price by Application (2016-2021) & (USD/Pcs) Table 48. Global Neurofibromatoses Type II Therapecutics Price Forecast by Application (2022-2027) & (USD/Pcs) Table 49. North America Neurofibromatoses Type II Therapecutics Sales by Type (2016-2021) & (K Pcs) Table 50. North America Neurofibromatoses Type II Therapecutics Sales by Type (2022-2027) & (K Pcs) Table 51. North America Neurofibromatoses Type II Therapecutics Revenue by Type (2016-2021) & (US$ Million) Table 52. North America Neurofibromatoses Type II Therapecutics Revenue by Type (2022-2027) & (US$ Million) Table 53. North America Neurofibromatoses Type II Therapecutics Sales by Application (2016-2021) & (K Pcs) Table 54. North America Neurofibromatoses Type II Therapecutics Sales by Application (2022-2027) & (K Pcs) Table 55. North America Neurofibromatoses Type II Therapecutics Revenue by Application (2016-2021) & (US$ Million) Table 56. North America Neurofibromatoses Type II Therapecutics Revenue by Application (2022-2027) & (US$ Million) Table 57. North America Neurofibromatoses Type II Therapecutics Sales by Country (2016-2021) & (K Pcs) Table 58. North America Neurofibromatoses Type II Therapecutics Sales by Country (2022-2027) & (K Pcs) Table 59. North America Neurofibromatoses Type II Therapecutics Revenue by Country (2016-2021) & (US$ Million) Table 60. North America Neurofibromatoses Type II Therapecutics Revenue by Country (2022-2027) & (US$ Million) Table 61. Europe Neurofibromatoses Type II Therapecutics Sales by Type (2016-2021) & (K Pcs) Table 62. Europe Neurofibromatoses Type II Therapecutics Sales by Type (2022-2027) & (K Pcs) Table 63. Europe Neurofibromatoses Type II Therapecutics Revenue by Type (2016-2021) & (US$ Million) Table 64. Europe Neurofibromatoses Type II Therapecutics Revenue by Type (2022-2027) & (US$ Million) Table 65. Europe Neurofibromatoses Type II Therapecutics Sales by Application (2016-2021) & (K Pcs) Table 66. Europe Neurofibromatoses Type II Therapecutics Sales by Application (2022-2027) & (K Pcs) Table 67. Europe Neurofibromatoses Type II Therapecutics Revenue by Application (2016-2021) & (US$ Million) Table 68. Europe Neurofibromatoses Type II Therapecutics Revenue by Application (2022-2027) & (US$ Million) Table 69. Europe Neurofibromatoses Type II Therapecutics Sales by Country (2016-2021) & (K Pcs) Table 70. Europe Neurofibromatoses Type II Therapecutics Sales by Country (2022-2027) & (K Pcs) Table 71. Europe Neurofibromatoses Type II Therapecutics Revenue by Country (2016-2021) & (US$ Million) Table 72. Europe Neurofibromatoses Type II Therapecutics Revenue by Country (2022-2027) & (US$ Million) Table 73. Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Type (2016-2021) & (K Pcs) Table 74. Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Type (2022-2027) & (K Pcs) Table 75. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue by Type (2016-2021) & (US$ Million) Table 76. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue by Type (2022-2027) & (US$ Million) Table 77. Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Application (2016-2021) & (K Pcs) Table 78. Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Application (2022-2027) & (K Pcs) Table 79. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue by Application (2016-2021) & (US$ Million) Table 80. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue by Application (2022-2027) & (US$ Million) Table 81. Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Region (2016-2021) & (K Pcs) Table 82. Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Region (2022-2027) & (K Pcs) Table 83. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue by Region (2016-2021) & (US$ Million) Table 84. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue by Region (2022-2027) & (US$ Million) Table 85. Latin America Neurofibromatoses Type II Therapecutics Sales by Type (2016-2021) & (K Pcs) Table 86. Latin America Neurofibromatoses Type II Therapecutics Sales by Type (2022-2027) & (K Pcs) Table 87. Latin America Neurofibromatoses Type II Therapecutics Revenue by Type (2016-2021) & (US$ Million) Table 88. Latin America Neurofibromatoses Type II Therapecutics Revenue by Type (2022-2027) & (US$ Million) Table 89. Latin America Neurofibromatoses Type II Therapecutics Sales by Application (2016-2021) & (K Pcs) Table 90. Latin America Neurofibromatoses Type II Therapecutics Sales by Application (2022-2027) & (K Pcs) Table 91. Latin America Neurofibromatoses Type II Therapecutics Revenue by Application (2016-2021) & (US$ Million) Table 92. Latin America Neurofibromatoses Type II Therapecutics Revenue by Application (2022-2027) & (US$ Million) Table 93. Latin America Neurofibromatoses Type II Therapecutics Sales by Country (2016-2021) & (K Pcs) Table 94. Latin America Neurofibromatoses Type II Therapecutics Sales by Country (2022-2027) & (K Pcs) Table 95. Latin America Neurofibromatoses Type II Therapecutics Revenue by Country (2016-2021) & (US$ Million) Table 96. Latin America Neurofibromatoses Type II Therapecutics Revenue by Country (2022-2027) & (US$ Million) Table 97. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Type (2016-2021) & (K Pcs) Table 98. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Type (2022-2027) & (K Pcs) Table 99. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue by Type (2016-2021) & (US$ Million) Table 100. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue by Type (2022-2027) & (US$ Million) Table 101. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Application (2016-2021) & (K Pcs) Table 102. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Application (2022-2027) & (K Pcs) Table 103. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue by Application (2016-2021) & (US$ Million) Table 104. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue by Application (2022-2027) & (US$ Million) Table 105. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country (2016-2021) & (K Pcs) Table 106. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country (2022-2027) & (K Pcs) Table 107. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue by Country (2016-2021) & (US$ Million) Table 108. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue by Country (2022-2027) & (US$ Million) Table 109. Arno Therapeutics Inc Corporation Information Table 110. Arno Therapeutics Inc Description and Major Businesses Table 111. Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 112. Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Product Table 113. Arno Therapeutics Inc Recent Developments Table 114. AstraZeneca Plc Corporation Information Table 115. AstraZeneca Plc Description and Major Businesses Table 116. AstraZeneca Plc Neurofibromatoses Type II Therapecutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 117. AstraZeneca Plc Neurofibromatoses Type II Therapecutics Product Table 118. AstraZeneca Plc Recent Developments Table 119. Beta Pharma Inc Corporation Information Table 120. Beta Pharma Inc Description and Major Businesses Table 121. Beta Pharma Inc Neurofibromatoses Type II Therapecutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 122. Beta Pharma Inc Neurofibromatoses Type II Therapecutics Product Table 123. Beta Pharma Inc Recent Developments Table 124. Lixte Biotechnology Holdings Inc Corporation Information Table 125. Lixte Biotechnology Holdings Inc Description and Major Businesses Table 126. Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 127. Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Product Table 128. Lixte Biotechnology Holdings Inc Recent Developments Table 129. Plex Pharmaceuticals Inc Corporation Information Table 130. Plex Pharmaceuticals Inc Description and Major Businesses Table 131. Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 132. Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Table 133. Plex Pharmaceuticals Inc Recent Developments Table 134. Recursion Pharmaceuticals Inc Corporation Information Table 135. Recursion Pharmaceuticals Inc Description and Major Businesses Table 136. Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 137. Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Table 138. Recursion Pharmaceuticals Inc Recent Developments Table 139. Key Raw Materials Lists Table 140. Raw Materials Key Suppliers Lists Table 141. Neurofibromatoses Type II Therapecutics Distributors List Table 142. Neurofibromatoses Type II Therapecutics Customers List Table 143. Neurofibromatoses Type II Therapecutics Market Trends Table 144. Neurofibromatoses Type II Therapecutics Market Drivers Table 145. Neurofibromatoses Type II Therapecutics Market Challenges Table 146. Neurofibromatoses Type II Therapecutics Market Restraints Table 147. Research Programs/Design for This Report Table 148. Key Data Information from Secondary Sources Table 149. Key Data Information from Primary Sources List of Figures Figure 1. Neurofibromatoses Type II Therapecutics Product Picture Figure 2. Global Neurofibromatoses Type II Therapecutics Market Share by Type in 2020 & 2027 Figure 3. AR-42 Product Picture Figure 4. FRAX-597 Product Picture Figure 5. Icotinib Hydrochloride Product Picture Figure 6. LB-201 Product Picture Figure 7. LB-205 Product Picture Figure 8. Others Product Picture Figure 9. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Application in 2020 & 2027 Figure 10. Clinic Figure 11. Hospital Figure 12. Home Care Figure 13. Neurofibromatoses Type II Therapecutics Report Years Considered Figure 14. Global Neurofibromatoses Type II Therapecutics Sales 2016-2027 (K Pcs) Figure 15. Global Neurofibromatoses Type II Therapecutics Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 16. Global Neurofibromatoses Type II Therapecutics Revenue 2016-2027 (US$ Million) Figure 17. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Region in Percentage: 2020 Versus 2027 Figure 18. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Region (2016-2021) Figure 19. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Region (2022-2027) Figure 20. North America Neurofibromatoses Type II Therapecutics Sales YoY (2016-2027) & (K Pcs) Figure 21. North America Neurofibromatoses Type II Therapecutics Revenue YoY (2016-2027) & (US$ Million) Figure 22. Europe Neurofibromatoses Type II Therapecutics Sales YoY (2016-2027) & (K Pcs) Figure 23. Europe Neurofibromatoses Type II Therapecutics Revenue YoY (2016-2027) & (US$ Million) Figure 24. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales YoY (2016-2027) & (K Pcs) Figure 25. Asia-Pacific Neurofibromatoses Type II Therapecutics Revenue YoY (2016-2027) & (US$ Million) Figure 26. Latin America Neurofibromatoses Type II Therapecutics Sales YoY (2016-2027) & (K Pcs) Figure 27. Latin America Neurofibromatoses Type II Therapecutics Revenue YoY (2016-2027) & (US$ Million) Figure 28. Middle East & Africa Neurofibromatoses Type II Therapecutics Sales YoY (2016-2027) & (K Pcs) Figure 29. Middle East & Africa Neurofibromatoses Type II Therapecutics Revenue YoY (2016-2027) & (US$ Million) Figure 30. The Top 10 and Top 5 Players Market Share by Neurofibromatoses Type II Therapecutics Sales in 2020 Figure 31. The Top 10 and Top 5 Players Market Share by Neurofibromatoses Type II Therapecutics Revenue in 2020 Figure 32. Neurofibromatoses Type II Therapecutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020 Figure 33. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2027) Figure 34. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2016-2027) Figure 35. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2027) Figure 36. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2016-2027) Figure 37. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2027) Figure 38. North America Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2016-2027) Figure 39. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2027) Figure 40. North America Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2016-2027) Figure 41. North America Neurofibromatoses Type II Therapecutics Sales Share by Country (2016-2027) Figure 42. North America Neurofibromatoses Type II Therapecutics Revenue Share by Country (2016-2027) Figure 43. U.S. Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 44. Canada Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 45. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2027) Figure 46. Europe Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2016-2027) Figure 47. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2027) Figure 48. Europe Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2016-2027) Figure 49. Europe Neurofibromatoses Type II Therapecutics Sales Share by Country (2016-2027) Figure 50. Europe Neurofibromatoses Type II Therapecutics Revenue Share by Country (2016-2027) Figure 51. Germany Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 52. France Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 53. U.K. Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 54. Italy Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 55. Russia Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 56. Asia Pacific Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2027) Figure 57. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2016-2027) Figure 58. Asia Pacific Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2027) Figure 59. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2016-2027) Figure 60. Asia Pacific Neurofibromatoses Type II Therapecutics Sales Share by Region (2016-2027) Figure 61. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue Share by Region (2016-2027) Figure 62. China Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 63. Japan Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 64. South Korea Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 65. India Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 66. Australia Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 67. Taiwan Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 68. Indonesia Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 69. Thailand Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 70. Malaysia Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 71. Philippines Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 72. Latin America Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2027) Figure 73. Latin America Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2016-2027) Figure 74. Latin America Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2027) Figure 75. Latin America Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2016-2027) Figure 76. Latin America Neurofibromatoses Type II Therapecutics Sales Share by Country (2016-2027) Figure 77. Latin America Neurofibromatoses Type II Therapecutics Revenue Share by Country (2016-2027) Figure 78. Mexico Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 79. Brazil Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 80. Argentina Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 81. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2027) Figure 82. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2016-2027) Figure 83. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2027) Figure 84. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2016-2027) Figure 85. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Share by Country (2016-2027) Figure 86. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue Share by Country (2016-2027) Figure 87. Turkey Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 88. Saudi Arabia Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 89. U.A.E Neurofibromatoses Type II Therapecutics Revenue (2016-2027) & (US$ Million) Figure 90. Neurofibromatoses Type II Therapecutics Value Chain Figure 91. Neurofibromatoses Type II Therapecutics Production Process Figure 92. Channels of Distribution Figure 93. Distributors Profiles Figure 94. Bottom-up and Top-down Approaches for This Report Figure 95. Data Triangulation Figure 96. Key Executives Interviewed

Arno Therapeutics Inc AstraZeneca Plc Beta Pharma Inc Lixte Biotechnology Holdings Inc Plex Pharmaceuticals Inc Recursion Pharmaceuticals Inc